Soliris and Multiple sclerosis - a phase IV clinical study of FDA data

Summary:

Multiple sclerosis is reported as a side effect among people who take Soliris (eculizumab), especially for people who are female, 30-39 old, have been taking the drug for < 1 month also take Tysabri, and have Haemolytic uraemic syndrome.

The phase IV clinical study analyzes which people have Multiple sclerosis when taking Soliris. It is created by eHealthMe based on reports of 58,774 people who have side effects when taking Soliris from the FDA, and is updated regularly.

What is Soliris?

Soliris has active ingredients of eculizumab. It is often used in paroxysmal nocturnal hemoglobinuria (pnh). eHealthMe is studying from 58,821 Soliris users. Check the latest studies of Soliris.

What is Multiple sclerosis?

Multiple sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath) is found to be associated with 1,090 drugs and 1,358 conditions by eHealthMe. Check the latest studies of Multiple sclerosis.

On Jun, 12, 2026

58,774 people reported to have side effects when taking Soliris.
Among them, 12 people (0.02%) have Multiple sclerosis.

Among these 12 people:

How long have people been on Soliris when they have Multiple sclerosis? *

What is the gender of people who have Multiple sclerosis when taking Soliris? *

female: 54.55 %
male: 45.45 %

What is the age of people who have Multiple sclerosis when taking Soliris? *

What are other drugs people take besides Soliris? *

Tysabri: 2 people, 16.67%
Promacta: 1 person, 8.33%
Maxalt: 1 person, 8.33%
Keppra: 1 person, 8.33%
Benadryl: 1 person, 8.33%

What are other side effects people have besides Multiple sclerosis? *

Fatigue (feeling of tiredness): 4 people, 33.33%
Weakness: 2 people, 16.67%
Blood Lactate Dehydrogenase Increased: 2 people, 16.67%
Mobility Decreased (ability to move is reduced): 2 people, 16.67%
Haemoglobin Decreased: 2 people, 16.67%
Gait Disturbance: 2 people, 16.67%
Fever: 2 people, 16.67%
Pain: 2 people, 16.67%
Common Peroneal Nerve Dysfunction (dysfunction of nerve controlling movement and sensation to the lower leg, foot and toes): 1 person, 8.33%
Gastrointestinal Disorder (functional problems of gastrointestinal tract): 1 person, 8.33%

What are the existing conditions these people have? *

Haemolytic Uraemic Syndrome (blood clotting disease caused by e. coli infection, birth control pills, pneumonia, medications, and more): 5 people, 41.67%
Paroxysmal Nocturnal Haemoglobinuria (haemoglobin in the urine): 4 people, 33.33%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 1 person, 8.33%
Myasthenia Gravis (a chronic condition that causes muscles to tire and weaken easily): 1 person, 8.33%
Migraine (headache): 1 person, 8.33%
High Blood Pressure: 1 person, 8.33%
Cystitis Interstitial (unknown cause characterized by bladder pain): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Soliris and have Multiple sclerosis?

- Check whether Multiple sclerosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Soliris:

Soliris (58,821 reports)

Browse all side effects of Soliris:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Multiple sclerosis:

Multiple sclerosis (1,090 drugs)

Browse all the conditions that are associated with Multiple sclerosis:

Multiple sclerosis (1,358 conditions)

Related publications that referenced our studies

Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on eculizumab (the active ingredients of Soliris) and Soliris (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.